Loupakis, Fotios
 Distribuzione geografica
Continente #
NA - Nord America 2.140
AS - Asia 192
EU - Europa 118
SA - Sud America 2
Totale 2.452
Nazione #
US - Stati Uniti d'America 2.137
CN - Cina 125
SG - Singapore 57
IT - Italia 30
FI - Finlandia 21
DE - Germania 20
GB - Regno Unito 15
SE - Svezia 13
FR - Francia 10
IN - India 6
UA - Ucraina 5
CA - Canada 3
IE - Irlanda 3
CL - Cile 2
IR - Iran 2
KH - Cambogia 1
MK - Macedonia 1
PK - Pakistan 1
Totale 2.452
Città #
Fairfield 456
Chandler 225
Woodbridge 188
Ashburn 184
Cambridge 179
Seattle 178
Houston 136
Wilmington 117
Ann Arbor 99
San Diego 49
Singapore 44
Beijing 31
Medford 27
Princeton 27
Des Moines 21
Helsinki 21
Padova 12
Boardman 10
Los Angeles 10
Saint Louis 10
Jinan 9
Nanchang 9
Nanjing 8
Changsha 7
Roxbury 7
Hefei 6
London 6
New York 6
Santa Clara 6
Guangzhou 5
Kunming 5
Dallas 3
Dublin 3
Kilburn 3
Munich 3
Ningbo 3
Taizhou 3
Tappahannock 3
Bergamo 2
Chengdu 2
Hangzhou 2
Hebei 2
Kharkiv 2
Lanzhou 2
Longobucco 2
New Bedfont 2
Santiago 2
Seregno 2
Shanghai 2
Shenyang 2
Soemmerda 2
Tehran 2
Terni 2
Trento 2
Cesena 1
Chicago 1
Chongqing 1
Dolo 1
Dongguan 1
Elk Grove Village 1
Erding 1
Haikou 1
Hanover 1
Mardan 1
Norwalk 1
Ogden 1
Ottawa 1
Phnom Penh 1
Phoenix 1
Pisa 1
Prescot 1
Pune 1
Quzhou 1
Redwood City 1
San Francisco 1
Stockholm 1
Taiyuan 1
Tianjin 1
Toronto 1
Trieste 1
Wenzhou 1
Zhengzhou 1
Totale 2.179
Nome #
Class 1, 2 and 3 BRAF mutated metastatic colorectal cancer: a detailed clinical, pathological and molecular characterization 171
Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases 149
BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling 137
An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer 130
LONG-NONCODING RNAs in gastroesophageal cancers 128
CK7 and consensus molecular subtypes as major prognosticators in V600E BRAF mutated metastatic colorectal cancer 125
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 116
miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis 112
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study 112
Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases 106
Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patients’ Prognosis 105
PD-L1 expression in gastroesophageal dysplastic lesions 94
Precision medicine in cholangiocarcinoma 89
Tumor mutation burden: From comprehensive mutational screening to the clinic 78
Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer? 73
Correction to: Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases (Cancer Cell International (2018) 18 (131) DOI: 10.1186/s12935-018-0634-8) 73
Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status 73
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer 73
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population 68
PTEN in colorectal cancer: Shedding light on its role as predictor and target 65
Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis 63
Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives 62
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 61
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis 60
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 59
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 56
Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes 46
Totale 2.484
Categoria #
all - tutte 9.714
article - articoli 9.714
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.428


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020732 0 0 37 205 56 46 91 76 86 51 42 42
2020/2021490 33 107 21 25 14 46 21 64 55 54 29 21
2021/2022460 21 55 51 34 25 17 42 44 14 10 47 100
2022/2023374 71 54 5 72 37 32 1 27 42 9 19 5
2023/2024184 11 40 22 15 12 20 19 2 6 9 13 15
2024/202574 2 46 26 0 0 0 0 0 0 0 0 0
Totale 2.484